Showing results (41-50 of 140) with videos related to
Sort By:
Pageof 14
Springerplus|June 14, 2014
Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimensRyan N Hansen, Scott D Ramsey, Deepa Lalla, et al.Plos One|May 5, 2021
Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapyJason J Zoeller, Michael F Press, Laura M Selfors, et al.Breast Cancer Research and Treatment|June 9, 2019
Clinical features of pseudocirrhosis in metastatic breast cancerCaspian Oliai, Michael L Douek, Caelainn Rhoane, et al.Targeted Oncology|October 18, 2019
Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to TrastuzumabHans-Christian Kolberg, Marco Colleoni, Patricia Santi, et al.Annals of the New York Academy of Sciences|August 16, 2014
Antibody-drug conjugates: an emerging modality for the treatment of cancerMauricio Leal, Puja Sapra, Sara A Hurvitz, et al.Breast (Edinburgh, Scotland)|May 9, 2025
Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologistsHope S Rugo, Aditya Bardia, William J Gradishar, et al.JCO Oncology Practice|May 11, 2023
Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health RecordsLetizia Polito, Jinjoo Shim, Sara A Hurvitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2010
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumabFabrice Andre, Mario Campone, Ruth O'Regan, et al.Brain, Behavior, and Immunity|February 7, 2024
Type I interferons, inflammation, and fatigue in a longitudinal RNA study of women with breast cancerJulienne E Bower, Patricia A Ganz, Michael R Irwin, et al.Future Oncology (London, England)|September 1, 2021
A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancerAditya Bardia, Sara A Hurvitz, Hope S Rugo, et al.Pageof 14